PUBLIC/PDR
030-03462

FOLEY & LARDNER

ATTORNEYS AT LAW

CHICAGO
JACKSONVILLE
LOS ANGELES
MADISON
MILWAUKEE
ORLANDO
SACRAMENTO

FIRSTAR CENTER
777 EAST WISCONSIN AVENUE
MILWAUKEE, WISCONSIN 53202-5367
TELEPHONE (414) 271-2400
FACSIMILE (414) 297-4900

SAN DIEGO
SAN FRANCISCO
TALLAHASSEE
TAMPA
WASHINGTON, D.C.
WEST PALM BEACH

WRITER'S DIRECT LINE
(414) 297-5656

EMAIL ADDRESS
rhart@foleylaw.com.

CLIENT/MATTER NUMBER
010124-0207

January 8, 1999

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Nuclear Regulatory Commission
801 Warrenville Road
Lisle, IL 60532-4351

Re: Name Change for St. Luke's Medical Center, Inc.

Dear Sir or Madam:

Effective December 30, 1998, St. Luke's Medical Center, Inc. (the "Corporation") changed its name to Aurora Health Care Metro, Inc. Attached please find a copy of the Corporation's Restated Articles of Incorporation filed with the Wisconsin Secretary of State (see Article I for the language changing the name).

The Corporation owns and operates the following two hospitals:

1. St. Luke's Medical Center - License No. 48-01338-01
   2900 West Oklahoma Avenue
   Milwaukee, WI 53215

2. St. Luke's South Shore -License No. 48-08325-01
   5900 South Lake Drive
   Cudahy, WI 53110-8903

The two hospitals will continue to do business under their current "doing business as" names - St. Luke's Medical Center and St. Luke's South Shore. In addition, there will be no change in ownership, activities, personnel, operations, services, programs, etc. This is simply a cosmetic name change.

9901280282 990108
PDR ADOCK 03003462
PDR
C

RECEIVED
JAN 12 1999
REGION III

0950 Pm; 1-8-99

001.458957.1

JAN 12 1999

If you have any questions, or need any additional information, please do not hesitate to call me at (414) 297-5656.

Very truly yours,

Rachelle R. Hart

Enclosure

cc: Donald J. Nestor
Mark Ambrosius
Michael P. Panosh

AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF
ST. LUKE'S MEDICAL CENTER, INC.
(to be hereafter known as Aurora Health Care Metro, Inc.)

St. Luke's Medical Center, Inc. amends its Articles of Incorporation to read as follows, and hereby adopts the following Restated Articles of Incorporation of said Corporation, which supersede and take the place of its heretofore existing Articles of Incorporation.

ARTICLE I
Name

The new name of the Corporation shall be Aurora Health Care Metro, Inc.

ARTICLE II
Purposes

The Corporation is organized and shall be operated exclusively for charitable, and educational purposes within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (or the corresponding provisions of any future United States Internal Revenue Law) (hereinafter the "Internal Revenue Code"); to engage in activities relating to the aforementioned purposes; and to invest in, receive, hold, use and dispose of all property, real or personal, as may be necessary or desirable to carry into effect the aforementioned purposes.

Notwithstanding any other provisions of these Articles of Incorporation, the Corporation shall not carry on any activities not permitted to be carried on (a) by a corporation exempt from Federal income tax under Section 501(c)(3) of the Internal Revenue Code or (b) by a corporation, contributions to which are deductible under Sections 170(c)(2), 2055(a)(2), or 2522(a)(2) of the Internal Revenue Code.

ARTICLE III
Powers

The Corporation shall have all powers conferred upon nonstock, nonprofit corporations organized under Chapter 181 of the Wisconsin Statutes and any successor provisions thereto now enacted or hereafter amended but shall exercise such powers only in fulfillment of its above-stated purposes.

The Corporation shall not engage in any of the following activities:

(1) The Corporation shall not participate in, or intervene in (including the publishing or distributing of statements), any political campaign on behalf of (or in opposition to) any candidate for public office.

(2) No substantial part of the activities of the Corporation shall consist of carrying on propaganda, or otherwise attempting, to influence legislation; provided, however, that this provision shall not apply to activities consisting of carrying on propaganda, or otherwise attempting, to influence legislation, to the extent the Corporation has made an election pursuant to and remains in compliance with the restrictions of Section 501(h) of the Internal Revenue Code.

(3) No dividends shall be paid and no part of the net earnings of the Corporation shall inure to the benefit of any private individual within the meaning of Section 501(c)(3) of the Internal Revenue Code.

ARTICLE IV
Members

The sole member of the Corporation shall be Aurora Health Care, Inc. Membership rights shall be set forth in the Bylaws of the Corporation.

ARTICLE V
Board of Directors

The affairs of the Corporation shall be managed by a Board of Directors. The current number of Directors constituting the Board of Directors is _____; hereafter, the number and manner of election or appointment of Directors and their terms of office shall be as provided in the Bylaws, but the number of Directors shall not be less than three (3).

ARTICLE VI
Dissolution and Liquidation

The Corporation may be dissolved upon the adoption of a plan to dissolve in the manner now or hereafter provided in the Wisconsin Statutes. In the event of dissolution of the Corporation, no liquidating or other dividends and no distribution of property owned by the Corporation shall be declared or paid to any private individual, but the net assets of the Corporation shall be distributed as follows:

(1) All liabilities and obligations of the Corporation shall be paid, satisfied and discharged, or adequate provision shall be made therefor;

(2) Remaining assets shall be distributed to one or more organizations described in Section 501(c)(3) of the Internal Revenue Code as determined in the plan to dissolve adopted in the manner set forth above in this Article VI. Any assets not disposed of pursuant to the foregoing provisions shall be distributed by the circuit court of the county in which the principal office of the Corporation is located to one or more organizations described in Section 501(c)(3) of the Internal Revenue Code, or to a governmental unit referred to in Section 170(c)(1) of the Internal Revenue Code exclusively for public purposes, as such court shall determine.

ARTICLE VII
Amendment

These Articles may be amended from time to time by the Member.

ARTICLE VIII
Miscellaneous

Section 1. The name and address of the registered agent of the Corporation is G. Edwin Howe, c/o Aurora Health Care, Inc., 3000 West Montana Avenue, Milwaukee, Wisconsin 53215.

Section 2. The mailing address in Wisconsin of the principal office of the Corporation is in Milwaukee County at 2424 South 90th Street, Suite 414, West Allis, Wisconsin 53227.

~~Section 3. The effective date of these Amended and Restated Articles of Incorporation shall be January 1, 1999, or the date of the filing of these Amended and Restated Articles of Incorporation with the Wisconsin Department of Financial Institutions, whichever is later.~~

The foregoing Amended and Restated Articles of Incorporation of this Corporation were approved by the sole member by a majority vote of the directors of the sole member at a meeting of such directors duly called and held on September 15, 1998.

IN WITNESS WHEREOF, I have hereunto set my hand this 19th day of November 1998.

AURORA HEALTH CARE METRO, INC.

STATE OF WISCONSIN
FILED
DEC 30 1998
DEPARTMENT OF
FINANCIAL INSTITUTIONS

By: Mark Ambrosius
Its: President

Attest: Karen J. Schultz
Its: Secretary Assistant Secretary

This document was drafted by and should be returned to Lynette M. Zigman, Foley & Lardner, 777 E. Wisconsin Ave., Suite 3600, Milwaukee, Wisconsin 53202-5367, (414) 297-5733. This instrument should be recorded in Milwaukee County.

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 7 PAGES

Amendment No. 96

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated February 4, 1998,
1. St. Luke's Medical Center	3. License number 48-01338-01 is amended in its entirety to read as follows:
2. 2900 West Oklahoma Avenue P. O. Box 2901 Milwaukee, WI 53201-2901	4. Expiration date February 28, 2005 5. Docket No. 030-03419 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (not to exceed 9.9 curies)
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500	E. As needed
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed
G. Uranium depleted in Uranium-235	G. Cadmium plated metal	G. As needed
H. Hydrogen-3	H. Foil sources (contained in a Barber Coleman Detector Cell Model No. 5120)	H. No single source to exceed 300 millicuries
I. Hydrogen-3	I. Any	I. 20 millicuries
J. Chromium-51	J. Any	J. 50 millicuries
K. Phosphorous-32	K. Any	K. 10 millicuries
L. Iodine-125	L. Any	L. 2 millicuries

9805220162 7pp.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 7 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-01338-01

Docket or Reference Number
030-03419

Amendment No. 96

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
M. Cesium-137	M. Sealed source (Amersham Model 77302)	M. One source not to exceed 150 millicuries
N. Carbon-14	N. Pre-packaged kits	N. 5 millicuries
O. Gadolinium-153	O. Sealed source (Lunar Model GD Series)	O. 1.5 curies
P. Gadolinium-153	P. Sealed sources (Isotope Product Laboratories Code HEGL-0022)	P. 3 sources, not to exceed 70 millicuries each
Q. Iridium-192	Q. Sealed sources (RTS 721, RTS 724 or BYK Mallinckrodt, Model GM 212.03-000)	Q. 2 sources, not to exceed 12 curies each
R. Carbon-14	R. Any	R. 5 millicuries
S. Sulfur-35	S. Any	S. 10 millicuries

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400.

E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

F. In vitro studies.

G. Shielding in a linear accelerator.

H. To be used in a Barber Coleman Series 5000 gas chromatography for sample analysis.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-01338-01

Docket or Reference Number
030-03419

Amendment No. 96

I. To be used for in vitro laboratory testing and animal studies.

J. To be used for in vitro radioimmunoassay.

K. To be used for in vitro laboratory testing.

L. To be used for in vitro laboratory testing.

M. To be used in an Amersham Model 773 instrument calibration device for calibration of the licensee's survey instruments.

N. To be used for in-vitro studies.

O. For storage only incident to final disposal.

P. Two sources to be used in a Picker International Transmission Line Source Housing STEP device for medical radiography in humans. One source in its shipping container for replacement of the source.

Q. One source to be used in an Isotopen-Technik Dr. Sauerwein GMBH Gammamed 12i High Dose Rate remote afterloading brachytherapy device for interstitial, intraluminal, and intracavitary radiotherapy in humans. One source in its shipping container for source replacement.

R. To be used for "in-vitro" studies.

S. To be used for "in-vitro" studies.

CONDITIONS

10. Locations of Use:

A. Licensed material shall be received, stored and used at the licensee's facilities located at St. Luke's Medical Center, 2900 West Oklahoma Avenue, Milwaukee, Wisconsin.

B. Licensed material for animal studies only may be used at St. Luke's Hospital Conference Center, Endocrine Research Laboratory, 2601 West Oklahoma Avenue, Milwaukee, Wisconsin.

11. Radiation Safety Officer: Douglas J. Simpkin, Ph.D.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 4 OF 7 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-01338-01

Docket or Reference Number
030-03419

Amendment No. 96

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
A. David L. Yuille, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, 31.11 and gadolinium-153 in STEP device for medical radiography.
B. Karl W. Schmitt, M.D.	10 CFR 35.100 and 31.11.
C. Kenneth A. Klein, M.D.	10 CFR 35.400.
D. Marcia J. S. Richards, M.D.	10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.
E. James E. Bruckman, M.D.	10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.
F. Walter Wong, M.D.	10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.
G. Mitchell H. Pincus, M.D.	10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.
H. Douglas J. Simpkin, Ph.D.	Subitem 6.M. and materials in 10 CFR 35.400, limited to instrument calibration.
I. J. Joseph Allen, M.S.	Subitem 6.M. and materials in 10 CFR 35.400, limited to instrument calibration.
J. Hershell Raff, Ph.D.	Hydrogen-3 for in-vitro studies and animal studies, and iodine-125 for in-vitro studies.
K. Tina Trevor, Ph.D.	Hydrogen-3, phosphorus-32, carbon-14 and sulfur-35 for in-vitro studies.
L. Martin K. Oaks, Ph.D.	Hydrogen-3, phosphorus-32, and chromium-51 for in-vitro studies.
M. William J. Pao, M.D.	10 CFR 35.400, depleted uranium and iridium-192 in HDR remote afterloading brachytherapy device.
N. James H. Taylor, M.D.	10 CFR 35.400.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-01338-01

Docket or Reference Number
030-03419

Amendment No. 96

O.	Aaron M. Kistler, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, 31.11 and gadolinium-153 in STEP device for medical radiography.
P.	Xiao-Rong Zhu, Ph.D	Subitem 6.M. and materials in 10 CFR 35.400, limited to instrument calibration.
Q.	Joseph Blechinger, Ph.D.	Subitem 6.M. and materials in 10 CFR 35.400, limited to instrument calibration.
R.	Ann Le Fever, Ph.D.	Subitems 6.I., 6.N., 6.J. 6.K. and 6.L., limited to in-vitro studies.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. In lieu of 10 CFR 35.404(a), immediately after retracting the source from the patient into its shielded position in the remote afterloading device, a radiation survey shall be made of the patient and the remote afterloading device with a portable radiation detection survey instrument to conform that the source has been removed from the patient. Records of the survey shall be maintained in lieu of the record required in 10 CFR 35.404(b).

15. In lieu of the source inventory required in 10 CFR 35.406, the licensee shall:

    A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each remote afterloading brachytherapy procedure.

    B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.

    C. Make a record of the survey including the survey instrument used, dose rate expressed in mrem/hr (μSieverts/hr), time, date and name of the individual making the survey.

    D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).

16. Prior to initiation of a treatment program, and subsequent to each source exchange using the Isotopen-Technik Dr. Sauerwein GMBH Gammamed 12i HDR remote afterloading brachytherapy device, radiation surveys and tests shall be performed in accordance with the following:

    A radiation survey shall be made of:

    (1) The irradiator source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall not exceed 1 milliroentgen per hour.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 6 OF 7 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-01338-01

Docket or Reference Number
030-03419

Amendment No. 96

(2) All areas adjacent to the treatment room with the source in the "irradiation" position. The survey shall clearly establish:

(a) That radiation levels in restricted areas are not likely to cause personnel exposure in excess of the limits specified in 10 CFR 20.1201.

(b) That radiation levels in unrestricted areas do not exceed the limits specified in 10 CFR 20.1301.

17. The following shall be performed only by manufacturer's representatives or persons specifically authorized by the Commission or an Agreement State to perform such services:

A. Installation and replacement of the sealed sources contained in the Isotopen-Technik Dr. Sauerwein GMBH Gammamed 12i HDR remote afterloading brachytherapy device(s).

B. Any maintenance or repair operations on the remote afterloading brachytherapy unit(s) listed in Item 9., Subitem Q involving work on the source safe, the source drive unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

18. A. Access to the rooms housing the Isotopen-Technik Dr. Sauerwein GMBH Gammamed 12i HDR remote afterloading brachytherapy device shall be [redacted] by a door at each entrance.

B. The entrance to the irradiation room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

C. Electrical interlocks on the entrance door to the irradiation room shall be tested for proper operation at least once each day of use.

D. In the event of malfunction of the door interlock, the irradiation device shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 7 OF 7 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-01338-01

Docket or Reference Number
030-03419

Amendment No. 96

19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application August 23, 1994 (with attachments); and

B. Letters dated January 11, 1995 (with attachments) and March 1, 1995 (with attachments, April 6, 1995 (with attachment), September 29, 1995 (with attachments, excluding attachment K) and April 12, 1996, July 31, 1996, September 25, 1997 (with attachments, excluding request in item 1 to authorize Dr. Trevor for iodine-125 and chromium-51) and February 4, 1998.

UNITED STATES NUCLEAR REGULATORY COMMISSION

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 12 1998

By Colleen C. Casey
Colleen C. Casey
Materials Licensing Branch
Region III

NRC FORM 374 (7-94)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 46

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. St. Luke's South Shore	In accordance with letter dated October 22, 1996 3. License Number 48-08325-01 is amended in its entirety as follows:
2. 5900 South Lake Drive Cudahy, WI 53110	4. Expiration Date March 31, 2005
	5. Docket or Reference No. 030-03462

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133)	B. As needed
C. Any byproduct material identified in 10 CFR 31.11	C. Prepackaged Kits	C. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding Xenon-133).

C. In vitro studies.

NRC FORM 374A (7-94) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number: 48-08325-01

Docket or Reference Number: 030-03462

Amendment No. 46

CONDITIONS

10. Location of Use: 5900 South Lake Drive, Cudahy, Wisconsin 53110.

11. Radiation Safety Officer: Douglas J. Simpkin, Ph.D.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
A. Daniel Rapp, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
B. Mack Karnes, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
C. Werner Kordas, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
D. Lynn M. Gilles, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
E. Jill A. Stephens, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
F. Lawrence M. Dubin, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
G. Keith G. Bernard, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.
H. Robert Allen Low, M.D.	10 CFR 35.100, 35.200 (excluding Xenon-133) and 31.11.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

NRC FORM 374A (7-94) U.S. NUCLEAR REGULATORY COMMISSION

License Number 48-08325-01

Docket or Reference Number 030-03462

Amendment No. 46

MATERIALS LICENSE
SUPPLEMENTARY SHEET

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 20, 1994; and

B. Letters dated October 3, 1994, March 1, 1995, April 17, 1996, and October 22, 1996 (with attachments).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date 11/8/96

By James Gallagher
Nuclear Materials Licensing Branch, Region III

DATE: 1-19-99

CORRESPONDENCE CLARIFICATION SHEET

REVIEWER: ~~MONTE PHILLIPS/SANDY~~ FRAZIER Debbie

LICENSEE: ST. LUKES

LICENSE NUMBER: 48-01338-01

The following correspondence has been received from the above licensee and it is not clear what action(s) is(are) required: Please review this correspondence and indicate which of the following applies, and please return to Debbie Hersey, or Ryan Te, as soon as possible.

☐ Additional Information to Control No. _____.
Process in as a new action, additional information, and no fee required.

☐ Process as new licensing action. Review has already been started on Control No._____ and this information cannot be combined with current in-house action.

☐ Can be combined with Control No. _____. Review has not started.

☒ Appears to be information for the license file - file it. 48-01338-01 & 48-08325-01

☐ Licensee is adding Nuclear Pharmacists.

Amendment is necessary _____. Amendment is not necessary _____. (Information for license file) (CF)

☐ Licensee is adding authorized users.

A check is included _____. No check is included _____.

Amendment is necessary _____. Amendment is not necessary _____. (This is a Notification)

☐ Process in as a new licensing action:

A. Amendment _____
B. Renewal _____
C. New License Application_____

☐ Other:_____

Thank You For Your Help!!! 01/28/98